According to the CDC, only 4.2 million people in the United States have received the full program of currently licensed vaccines.
Micah Green/Bloomberg News
29. January 20, 11:25 a.m. Eastern time.
Wall Street has crowned its Covid 19 vaccine winners. But a follower is still good enough to have a return to normal life in sight.
Johnson & Johnson
said Friday morning that its vaccine was 66% effective in preventing moderate to severe illness in patients 28 days after vaccination. This result is well below what other manufacturers have reported in clinical trials and below the expectations of Wall Street analysts, who had generally hoped for 80% efficacy. Johnson & Johnson shares were sold Friday morning, while
that the stock would continue to grow. This market reaction is perfectly logical, given that other manufacturers have reported yields in excess of 90 %. share of departures
which announced solid data on Thursday, with an increase of more than 50%.
These more effective vaccines will undoubtedly play an important role in focusing on high-risk patients and protecting against new strains of the virus that are of concern to public health authorities. The efficacy of the J&J vaccine is comparable to that of a good version of the flu vaccine. The vaccine is generally safe and well-tolerated, meaning regulators are likely to approve the use of the shot in emergencies next month. It is important to note that serious illness was reduced by 85% over the course of the study, J&J said.
When responding to a pandemic, speed can be as useful as strength. In the United States, only 4.2 million people have received two doses of the vaccine, according to the Centers for Disease Control and Prevention.
That’s where J&J has a distinct advantage: Their stand is one shot, while other enemies require two. A more comfortable suggestion makes it easier to convince patients to take a picture. Equally important, the vaccine can be stored for months in a regular refrigerator. The J&J syringe can be easily administered in traditional locations such as doctor’s offices and pharmacies. And because demand for vaccines still far exceeds supply, large segments of the population, such as healthy young patients, do not need the strongest protection immediately.
Mass vaccination with a J&J efficacy profile would not completely eradicate Covid-19. However, given the serious economic and social consequences of limiting normal daily life, full eradication should not be a condition for opening schools and restaurants and expanding travel opportunities. By reducing the pressure on health care systems and workers, the risk of rediscovery will be much less frightening, even if Covid-19 continues to spread.
As for J&J, the company’s outlook for this year, announced earlier this week, shows no revenue for the Covid-19 vaccine, and the stock is valued at fair value. Expect Wall Street to get rid of the current frustration soon.
President Biden announced that he plans to ship more Pfizer and Moderna vaccines to the states over the next three weeks and purchase enough additional doses to vaccinate most of the U.S. population by the end of the summer. Photo: Doug Mills/Getty Images
Email Charlie Grant at [email protected]
Copyright ©2020 Dow Jones & Company, Inc. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
Published on January 30, 2021 in a print publication titled Even with 66% efficacy, J&J’s vaccine is a winner.